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We present a case of highly elevated tenfold rise of serum chromogranin A in a young, morbidly obese, hypertensive female being
investigated for pancreatic mass, weight loss, and elevated ESR. Following extensive noninvasive investigations, an ultrasound-
guided pancreatic biopsy confirmed benign haemorrhagic cyst. A clue to the etiology of the hyperchromogranin A was the elevated
serum gastrin level leading to suspicion of proton pump inhibitor administration confirmed by admittance to its use. Withdrawal
of the medication led to dramatic resolution of the neuroendocrine tumor marker.
1. Introduction
Chromogranin A (CgA) has shown to be a useful marker in
the diagnosis and followup of neuroendocrine tumors
(NETs). Its reliability in correctly diagnosing NETs is a grow-
ing concern [1]. Proton pump inhibitors (PPIs) being widely
used for treating upper gastrointestinal disorders including
gastroesophageal reflux disease (GORD) may cause serious
differential diagnostic problems with elevation of serumCgA
in suspected NETs [2]. As far as we know, there is no report
of this artefact causing diagnostic interference in subjects
with pancreatic mass requiring further characterization. We
report a case of highly elevated serum CgA in a patient with
pancreatic incidentaloma caused by PPI therapy.
2. Case Presentation
A 46-year-old morbidly obese Caucasian female was referred
by her general practitioner (GP) to rheumatologist for fur-
ther evaluation of 25 kilograms weight loss over a period of
one year associated with persistently elevated ESR of 60mm/
hr. Her history was remarkable for hypertension, depression,
and GORD. Medications disclosed at initial consultation
included verapamil SR 240mg/day for a well-controlled
hypertension. Clinical examination at presentation revealed
an obese woman with a bodymass index of 58 kg/m2 without
clinical features of Cushing’s syndrome. The rest of the phys-
ical examination was normal. All rheumatologic and vas-
culitic studies were unremarkable. As part of the work-up, an
ultrasound and CT scan showed pancreatic head mass mea-
sured 3.6 × 2.4 cm diameter. The radiological differentials
were cystoadenoma and adenocarcinoma. Followup liver
function test showed no evidence of biliary obstruction. Joint
gastroenterological and endocrine biochemical assessment
revealed normal serum glucose, glucagons, and vasoactive
intestinal peptide. Other tumor markers were undetectable.
Further investigations included normal findings for cortisol
rhythm and low dose dexamethasone suppression. Urinary
catecholamine and 5-hydroxy indole acetic acid excretion did
not suggest elevated hormonal activity. An initial serum CgA
measured by enzyme-linked immunosorbent assay (0.5U/L
detection limit; Dako, Denmark) was noted to be moderately
elevated 46.0U/L (normal < 17.2U/L) and rose to 176U/L
in 4 months (Figures 1 and 2). Simultaneous serum gastrin
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Figure 1: Marked escalation of serum chromogranin A levels 4
months after initial sampling on proton pump inhibitor rapid nor-
malisation after 3 weeks of its withdrawal.
level was elevated twice upper limit of normal 198 ng/L
(normal < 100 ng/L). Further clinical review highlighted
previously undisclosed usage of PPI, rabeprazole 40mg once
daily dating back to the twelve-month period of work-up.
This medication was then subsequently suspended resulting
in normalization of CgA (Figure 2) and subsequent 6-month
followup confirmed consistently undetectable serum CgA
levels while off the PPI. 131I-MIBG scintigraphy did not
show pathologic isotope accumulation and serial CT scan of
abdomen revealed no increase in size of the pancreatic mass.
Endoscopic ultrasound-guided fine needle biopsy confirmed
the lesion to be a benign pancreatic hemorrhagic cyst.
3. Discussion
We have demonstrated another evidence for dramatic rise
and fall of CgA in a patient who had been investigated for
marked weight loss and elevated ESR. Other biochemical
profiles were unremarkable, yet, elevation of the tumor
marker in the malignant range eventuated in significant
anxiety for both patient and doctors. It was not known to
us that the patient had been on PPI introduced during the
period of work-up by her GP for GORD. This was com-
plicated by an apparent weight loss possibly from anorexia
due to exacerbation of depression symptoms. The serum ESR
remained high throughout with no cause identified during
the course of investigation. While rising level of CgA is not
new in the literature [1, 2], the progressive rise of CgA in
association with symptoms particularly in an individual with
pancreatic mass was an interesting aspect of our report. Igaz
et al. reported a 7-fold rise of CgA due to PPI which was
normalized upon stoppage of the medication [3]. To our
knowledge, this is the first report of a very high level of serum
CgA of 10-fold magnitude due to ingestion of PPI.
Another interesting phenomenon highlighted by this case
is the report of rapid normalization of CgA after withdraw-
al of PPI in a subject presenting with a pancreatic non-
functioning incidentaloma. Similar findings were reported
in subjects with bilateral adrenal incidentaloma in which
persistently elevated CgA after adrenalectomy for phaeochro-
mocytoma was normalized only following suspension of PPI
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Figure 2: CT scan of the abdomen showing a 3.6 × 2.4 cm cystic
lesionwithin the uncinate process of the pancreas extending into the
pancreatic head.
[3]. Our report as well as others observations serve as a
reminder to clinicians to pay great attention to confounding
factors before pursuing invasive and costly procedures in
suspected cases of NETs. The fact that the serum gastrin level
was elevated in our patient pointed to a possible usage of PPI
which was confirmed on reviewing her medication history.
The pathogenesis of increased levels of CgA by PPI is
not clear. For instance, although hypergastrinemia induced
release of the tumor marker was hypothesized as a possible
explanation [4, 5], Gori et al. in fact reported lack of con-
comitant elevation of serum gastrin levels associated with
the use of PPI [6]. We measured this peptide simultaneous
with CgA and it was modestly elevated in keepingwith others
findings [4, 5]. Furthermore, other nonmalignant endocrine
conditions leading to hypergastrinemia were reported to
cause increased serum CgA [7]. Interestingly, recent reports
have suggested that chronic use and dose escalation of PPI
correlates with increased level of both CgA and serum
gastrin [3, 5]. Our patient was maintained on the same
dose of PPI throughout the period of use yet; in the last 4
months there was an alarmingly marked elevation of CgA.
Another possible reason for this might be poor preparation
for the CgA sampling such as nonfasting state [8]. Other
confounding factors including use of non-PPI medications
such as glucocorticoids were not contributory. On the other
hand, the period from withdrawal of PPI to subsequent CgA
decline was suggested in a recent report to be one week [3]
while others earlier proposed 7–10 days [2]. In our subject,
the decisive fasting serum CgA was analysed after complete
suspension of the PPI for a period of 3 weeks which led to
dramatic normalization of the tumor marker.
This case suggests that despite the potentially complex
pathophysiologic and biochemical pathways resulting in in-
creased CgA associated with a pancreatic mass in the context
of PPI usage, prompt normalization of CgA levels was
achieved upon PPI withdrawal. In order to save patients from
invasive, risk prone, and costly investigations, it is crucial that
guidelines are formulated that recommend that meticulous
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scrutiny of confounding factors is invoked. This should in-
clude comprehensive review of medications with particular
attention to undisclosed acid-suppressant therapy [9]. This
will certainly reduce the incidence of false positive diagnoses
of NETs and avert unnecessary anxiety and investigations.
We add this case to the growing list of reports of elevated
CgA in neuroendocrine incidentaloma and for the first
time report on the finding in a patient with a worrying
pancreatic mass hoping to better define the clinical work-up
of NETs and promote awareness to avoid unnecessary anxiety
potentially relating to misdiagnosis.
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